Skip to main content

Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

Publication ,  Journal Article
Chauvenet, AR; Martin, PL; Devidas, M; Linda, SB; Bell, BA; Kurtzberg, J; Pullen, J; Pettenati, MJ; Carroll, AJ; Shuster, JJ; Camitta, B
Published in: Blood
August 15, 2007

Pediatric Oncology Group (POG) protocol 9201 enrolled children with lesser-risk B-lineage acute lymphoblastic leukemia (ALL) defined by age (1-9), white blood cell count (WBC) less than 50 x 10(9)/L (50,000/microL), DNA findings of trisomies 4 and 10 (or DNA index > 1.16), and lack of overt central nervous system (CNS) leukemia. After vincristine, prednisone, and asparaginase induction, 650 of 653 eligible patients attained remission (3 induction deaths) and received 6 courses of intravenous methotrexate (1 g/m(2)) with daily mercaptopurine. Weekly intramuscular methotrexate was added during maintenance; pulses of vincristine and prednisone were administered with periodic intrathecal chemotherapy. Treatment duration was 2.5 years. No alkylators, epipodophylotoxins, anthracyclines, or radiation were given. The 6-year event-free survival (EFS) was 86.6% with overall survival (OS) of 97.2%. Patients with less than 5% marrow blasts on induction day 15 had superior EFS. A difference not reaching conventional statistical significance (P = .068) was noted for superior outcomes in patients with trisomies of chromosomes 4 and 10 versus those lacking double trisomies. Sex, ethnicity, CNS status, and WBC were not predictive. This indicates the great majority of children with lesser-risk B-lineage ALL are curable without agents with substantial late effects.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

ISSN

0006-4971

Publication Date

August 15, 2007

Volume

110

Issue

4

Start / End Page

1105 / 1111

Location

United States

Related Subject Headings

  • Vincristine
  • Treatment Outcome
  • Remission Induction
  • Prednisone
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Pilot Projects
  • Methotrexate
  • Mercaptopurine
  • Male
  • Injections, Spinal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chauvenet, A. R., Martin, P. L., Devidas, M., Linda, S. B., Bell, B. A., Kurtzberg, J., … Camitta, B. (2007). Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood, 110(4), 1105–1111. https://doi.org/10.1182/blood-2006-12-061689
Chauvenet, Allen R., Paul L. Martin, Meenakshi Devidas, Stephen B. Linda, Beverly A. Bell, Joanne Kurtzberg, Jeanette Pullen, et al. “Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.Blood 110, no. 4 (August 15, 2007): 1105–11. https://doi.org/10.1182/blood-2006-12-061689.
Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood. 2007 Aug 15;110(4):1105–11.
Chauvenet, Allen R., et al. “Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.Blood, vol. 110, no. 4, Aug. 2007, pp. 1105–11. Pubmed, doi:10.1182/blood-2006-12-061689.
Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, Pullen J, Pettenati MJ, Carroll AJ, Shuster JJ, Camitta B. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood. 2007 Aug 15;110(4):1105–1111.

Published In

Blood

DOI

ISSN

0006-4971

Publication Date

August 15, 2007

Volume

110

Issue

4

Start / End Page

1105 / 1111

Location

United States

Related Subject Headings

  • Vincristine
  • Treatment Outcome
  • Remission Induction
  • Prednisone
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Pilot Projects
  • Methotrexate
  • Mercaptopurine
  • Male
  • Injections, Spinal